Recombinant protein vaccine, VLP
Updated · Methodology
First line
HPV during breastfeeding. CDC ACIP 2024 and SEGO 2023 – fully compatible. If unvaccinated before pregnancy and ≤26 (or ≤45 depending on risk) – vaccinate postpartum.
Sources
ICD-10: Z23 · ICD-11: QC00
Contains virus-like particles (VLPs) of L1 capsid protein from nine HPV types: 6 and 11 (genital warts) and 16, 18, 31, 33, 45, 52, 58 (oncogenic). Adjuvant – aluminum hydroxyphosphate sulfate. 2–3 doses in girls 9–14, 3 doses in adults. Effectiveness against CIN 2+ cervical lesions 97%.
Not recommended in pregnancy (defer until after delivery). Accidental vaccination is safe; no need to terminate.
Fully compatible. Hale L1.
Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.
Opens the checker prefilled with this drug. Pick the second one from your regimen.
Summary of a multi-drug list →
Medicine list: everything you take in one place →
HPV vaccine, nonavalent is evaluated for the following indications with varying evidence strength: Vaccination during breastfeeding (evidence tier A). See the full indication matrix with dosing and citations above on this page.
Common side effects of HPV vaccine, nonavalent (≥ 1 in 100): Injection-site pain (90%), Low-grade fever (10%), Headache, Fatigue. See the Safety section for uncommon and serious reactions.
Not recommended in pregnancy (defer until after delivery). Accidental vaccination is safe; no need to terminate.
Fully compatible. Hale L1.
HPV vaccine, nonavalent is contraindicated in: Anaphylaxis to yeast or components; Pregnancy (defer doses until after delivery); Acute febrile illness. Full list in the Safety section.
Inactivated influenza vaccine, MMR – measles, mumps, rubella vaccine (live), Pneumococcal conjugate vaccine PCV20, RSV vaccine, recombinant (maternal), COVID-19 vaccine, mRNA (Moderna), Hepatitis A vaccine, inactivated, Tdap – tetanus, diphtheria, acellular pertussis vaccine, COVID-19 vaccine, mRNA (Pfizer-BioNTech)